Abstract:Abstract Background Metastatic bone disease is a frequent complication of advanced non-small-cell lung cancer and causes skeletal-related events which result in a poor prognosis. A standard method to assess the therapeutic response of bone metastases does not currently exist. We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine–cisplatin plus rh-endostatinfor previously untreated non-small cell lung cancer with bone metastases. Methods We did a phase 4, randomised, prospective, double-blind, placebo-controlled clinical trial in Shanghai Sixth Peopleu0027s Hospital, Shanghai, China. Inclusion criteria were non-small-cell lung cancer patients with bone metastases confirmed by pathology or cytology; available imaging data of pelvic metastatic lesions; aged 18 to 75 years old; expected survival at least 3 months; not receiving taxane, bevacizumab, thalidomide, rh-endostatin, or bisphosphonate; not having radiation therapy within 3 months of enrollment into study; normal results of routine blood tests, liver and kidney function, and electrocardiogram; absence of cardiovascular disease, autoimmune disease, vasculitis, severe infection, diabetes, and other concomitant disease; and signed informed consent. Exclusion criteria were receiving granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor during chemotherapy, intolerance to adverse reaction, and allergy to contrast agents. Patients were randomly assigned to treatment group and control group at a ratio of 2:1 by random code generation by an independent biostatistician in a double-blind fashion. Participants received either vinorelbine–cisplatin plus rh-endostatin or vinorelbine–cisplatin plus placebo. Vinorelbine (25 mg/m 2 ) and cisplatin (75 mg/m 2 ) were administered intravenously on the first day of a 21 day cycle. Patients received rh-endostatin (7·5 mg/m 2 ) or placebo on days 1–14 of a cycle. The primary end points were objective response rate (complete remission+partial remission)/total × 100) and disease control rate (complete remission+partial remission+stable disease)/total × 100). Measurements including K trans , K ep , and V e were evaluated by dynamic contrast-enhanced MRI before treatment and after completion of 2 treatment cycles. Blood concentrations of bone metabolites, tumour markers, and tumour vascular growth related factors were measured before and after treatment. Comparisons were made using paired t-test. Kaplan-Meier survival analysis was used to indicate the correlation between some measurements and progression-free survival or overall survival. The difference in K trans between patients who had partial remission or stable disease group and those who had disease progression was tested using the Chi-square test. All statistical analyses were performed with SPSS version 21.0. This trial was approved by the State Food and Drug Administration (No: S20050088) and China State Food and Drug Administration. The trial is registered with China Clinical Trials Registry, number chictr-ctr-09000569. Written informed consent and ethical approval was obtained. Findings We enrolled 33 patients (aged 52–70, 15 men and 18 women) of whom 28 were evaluable (20 in treatment group and 8 in control group). Five patients were excluded: 2 patients in treatment group and 1 patient in control group used granulocyte-macrophage colony stimulating factor, and 2 patients in the control group refused treatment. Objective response rate was higher (30% vs 0%; p Interpretation Addition of rh-endostatin to treatment with vinorelbine–cisplatin increased the treatment response in patients with non-small cell lung cancer and bone metastases. Quantitative analysis using dynamic contrast-enhanced MRI can be used to evaluate therapeutic response and to predict survival of bone metastases after anti-angiogenesis therapy. Limitations of this study include the small number of patients and the single-centre design. Funding National Natural Science Foundation of China [grant number 81201628].

Predictive value of serum VEGF in patients with advanced non-small cell lung cancer treated with vinorelbine

Randomized, Placebo-Controlled Study of Vinorelbine Plus Cisplatin with Celecoxib and Serum Vegf Before Treatment As A Biomarker for Patients with Advanced Non-Small Cell Lung Cancer.

Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.

Total and Not Bevacizumab-Bound Vascular Endothelial Growth Factor As Potential Predictive Factors to Bevacizumab-Based Chemotherapy in Colorectal Cancer.

Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diag-nosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF

Serum DKK-1 levels in the advanced non-small cell lung caner patients: a randomized clinical study on combination of celecoxib with cisplatin-based chemotherapy

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

[Serum Levels of Endostatin and VEGF in Non-Small Cell Lung Cancer Patients and the Relationship with the Clinical Pathophysiological Characteristics].

Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients

Clinical significance of serum VEGF in 78 patients with non-small cell lung cancer

Retrospective Analysis of 119 Chinese Noninflammatory Locally Advanced Breast Cancer Cases Treated with Intravenous Combination of Vinorelbine and Epirubicin As a Neoadjuvant Chemotherapy: a Median Follow-Up of 63.4 Months.

Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial

Risk Factors and Prognosis Value of Venous Thromboembolism in Patients with Advanced Non-Small Cell Lung Cancer: a Case-Control Study

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment A cohort study

Usefulness of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Treatment Response to Vinorelbine-Cisplatin with or Without Recombinant Human Endostatin in Bone Metastasis of Non-Small Cell Lung Cancer

Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer

Vinorelbine Alters lncRNA Expression in Association with EGFR Mutational Status and Potentiates Tumor Progression Depending on NSCLC Cell Lines’ Genetic Profile

Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways

Vinorelbine Plus Oxaliplatin in the Treatment of 26 Cases of Advanced Non-Small Cell Lung Cancer

A Randomised, Multicentre Open-Label Phase II Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of Oral Vinorelbine Plus Cisplatin Versus Intravenous Vinorelbine Plus Cisplatin in Chinese Patients with Chemotherapy-Naive Unresectable or Metastatic Non-Small Cell Lung Cancer.

Post-operative treatment with cisplatin and vinorelbine in Chinese patients with non-small cell lung cancer: a clinical prospective analysis of 451 patients.